Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations
Related Experiment Video
Updated: Jul 6, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Jennifer B Rosen1, Joel G Breman
1Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA. jennifer.rosen@uhmc.sunysb.edu
Insights
Intermittent preventive treatment with amodiaquine (IPTi) in infants reduced malaria fevers. This malaria control strategy may improve vaccine responses in children, warranting further investigation.
Area of Science:
- Global Health
- Immunology
- Pediatrics
Background:
- Malaria causes millions of deaths annually, primarily in young children in sub-Saharan Africa.
- Acute malaria is linked to diminished immune responses to essential childhood vaccines.
- Antimalarial drugs, including 4-aminoquinolones, may potentially suppress vaccine immunity.
Purpose of the Study:
- To investigate the impact of amodiaquine intermittent preventive treatment (IPTi) on malaria incidence in infants.
- To assess the safety and efficacy of IPTi when co-administered with routine infant vaccinations.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 291 infants aged 12-16 weeks in Tanzania.
- Infants received their third dose of combined diphtheria-tetanus-pertussis and poliomyelitis vaccines alongside IPTi or placebo.
- Malaria fevers were monitored over a 60-day period.
Main Results:
- Infants receiving amodiaquine IPTi experienced significantly fewer malaria fevers compared to the placebo group.
- The study demonstrated a reduction in malaria burden in infants receiving IPTi.
Conclusions:
- Co-administration of IPTi with routine infant immunizations is a viable strategy for malaria control.
- Further research is warranted due to the increasing overlap of malaria control and vaccination efforts.
- Increased travel to malaria-endemic regions necessitates understanding concurrent vaccination and chemoprophylaxis effects.
Context:
Malaria accounts for 1-3 million deaths yearly worldwide, mostly in children under 5 years of age in sub-Saharan Africa. Laboratory and clinical studies show an association between acute malaria and a decreased response to diphtheria and tetanus toxoids and to meningococcal, salmonella, and Haemophilus influenzae type b vaccinations. Malaria treatment, chemoprophylaxis, or other forms of parasite suppression might improve the immune response to childhood vaccinations. However, the antimalarial 4-aminoquinolones are immunodepressive, such that antimalarial drugs might depress the vaccine response.
Starting Point:
Last year, Julius Massaga and colleagues reported a randomised double-blinded placebo-controlled study in 291 infants aged 12-16 weeks in Tanzania (Lancet 2003; 361: 1853-60). At enrollment, children received their third dose of combined diphtheria-tetanus-pertussis and poliomyelitis expanded vaccines with the first of three daily doses of amodiaquine intermittent preventive treatment (IPTi) or placebo. After 60 days, children receiving amodiaquine had significantly fewer malaria fevers than controls.
Where Next:
The increasing concordance of malaria control and vaccination, movement toward co-administration of IPTi with immunisation, and the increase in travellers to malarious areas who receive concurrent vaccinations and chemoprophylaxis warrant further study.
Related Concept Videos
Preventive Healthcare Services
Sexually Transmitted Infections
Pharmacokinetics in Pediatric Patients: Drug Excretion
Microorganisms in Medicine and Therapeutics
Smallpox
Respiratory Syncytial Virus Disease

